E4412; A Phase 1 Study with an Expansion Cohort of the Combination of Ipilimumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma
This phase I trial studies the side effects and best dose of ipilimumab when given together with brentuximab vedotin in treating patients with relapsed or refractory Hodgkin lymphoma.
The purpose of this study is to determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLT) of the combination of brentuximab vedotin and ipilimumab, brentuximab vedotin and nivolumab, and brentuximab vedotin, ipilimumab, and nivolumab.
- IRB Number: 1310523566
- Research Study Identifier: TX3864
- Principal Investigator: Michael Robertson, MD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required